ClinicalTrials.gg
Status unknownNCT03422146Updated Feb 5, 2018

Antimicrobial and Clinical Efficacy of Cliradex® as Compared With I-Lid'n Lash® Hygiene in Treating Blepharitis

An interventional study of Tea Tree Oil (TTO) and I-Lid'n Lash® Hygiene in Blepharitis and Meibomian Gland Dysfunction, sponsored by Ottawa Hospital Research Institute. Status unknown at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-02-05.

Sponsored by Ottawa Hospital Research Institute · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2018), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Feb 2017, registered Dec 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Previous studies have shown the clinical and antimicrobial efficacy of eyelid hygiene with tea tree oil (TTO) in resolving chronic blepharitis. Cliradex® is a novel over-the-counter eyelid wipe which contains the most active ingredient of TTO. The present study is a single-centre, randomized, trial comparing Cliradex® eyelid hygiene and I-Lid 'n Lash® Hygiene, another over-the-counter eyelid wipe, without any medicinal ingredients, in treating chronic blepharitis. The Primary Outcome Measure will be the difference in change in the number of CFU's after 2 weeks treatment, between the groups. The Secondary Outcome Measure will be the difference in change in objective clinical signs and symptoms by performing a vision check, a questionnaire, and visual grading, of each participants' blepharitis after 2 weeks treatment, between the groups. The Tertiary Outcome Measures will be the difference in change in microbial CFUs and clinical signs and symptoms between the groups at the 4 and 6 week point, (2 and 4 weeks after discontinuing treatment), to evaluate if the treatment will produce a lasting effect.

Participants will be randomized into one of the treatment arms. They will use the appropriate treatment for two weeks. They will then be re-assessed. They will discontinue treatment at this time, and four weeks later, will be assessed one last time, to see if the temporary treatment provides a lasting effect. A sub-group of ten patients per group will also be randomized to an extra visit. This group will be assessed after two weeks of having stopped the wipes. The same testing and procedures will be performed at this appointment.

Read the detailed description

Previous studies have shown the clinical and antimicrobial efficacy of eyelid hygiene with tea tree oil (TTO) in resolving chronic blepharitis. This randomized, outcomes-assessor masked, clinical trial aims to determine the efficacy of Cliradex®, which contains the most active ingredient of (TTO), as compared with I-Lid 'n Lash® Hygiene, in treating chronic blepharitis

Blepharitis is a family of inflammatory disease processes of the eyelid. It can be divided anatomically into anterior and posterior blepharitis. Anterior blepharitis refers to inflammation mainly centered around the eyelashes and follicles, while the posterior variant involves the meibomian gland orifices. Anterior blepharitis usually is subdivided further into staphylococcal and seborrheic variants. Frequently, a considerable overlap exists in these processes in individual patients. Blepharitis often is associated with systemic diseases, such as rosacea and seborrheic dermatitis, as well as ocular diseases, such as dry eye syndromes, chalazion, trichiasis, conjunctivitis, and keratitis.1-3

The pathophysiology of blepharitis involves bacterial colonization of the eyelids. This results in direct microbial invasion of tissues, immune system-mediated damage, or damage caused by the production of bacterial toxins, waste products, and enzymes. Colonization of the lid margin is in-creased in the presence of seborrheic dermatitis or meibomian gland dysfunction.1-3

Blepharitis can be difficult to manage because it is often chronic or tends to recur. Despite the cause, eyelid hygiene is the cornerstone of treatment for most cases of blepharitis. This includes the use of commercially available over-the-counter lid cleansing wipes. Previous studies have shown the clinical and microbial efficacy of lid scrubs with tea tree oil (TTO) in resolving chronic blepharitis; however, lid scrubs based on TTO are not convenient for self-administration and cause irritation in some patients.4-11

Cliradex® (Bio-Tissue, Miami, FL) is a commercially available cosmetic pad containing the most active ingredient of TTO, which also exerts potent anti-microbial effects which may eliminate the need for systemic and/or topical antibiotic therapy for blepharitis.

In this trial, the investigators propose to conduct a randomized, outcomes assessor masked, clinical trial to determine the clinical and antimicrobial efficacy of Cliradex® and I-Lid 'n Lash® Hygiene, in improving the signs and symptoms of blepharitis, as well as decreasing the microbial flora in these patients.

02

Conditions studied

  • Blepharitis
  • Meibomian Gland Dysfunction
03

In context

Blepharitis

73 studies on the registry are indexed under Blepharitis; 9 are open to participants now.

This study's planned enrollment of 40 is below the median of 60 across 65 interventional studies indexed under Blepharitis.

Browse Blepharitis studies →

Lead sponsor

Ottawa Hospital Research Institute is the lead sponsor of 547 studies on the registry; 99 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with symptomatic blepharitis for duration of at least 3 months.
  • Male and female age range: > 18 years old.
  • All ethnic groups comparable with the local community.
  • Patients able and willing to cooperate with the plan.
  • Patients able and willing to complete all postoperative follow-up visits.
  • Able to understand and willing to sign a written .

Exclusion criteria

Exclusion Criteria:

  • Patients who are currently engaged in another clinical trial.
  • Patients who are unwilling or unable to give consent.
  • Patients who are unwilling to accept randomization.
  • Patients who will not be able to return for scheduled visits.
  • Children under 18.
  • Concomitant use of ophthalmic topical medications (excluding non-preserved tear substitutes).
  • Concomitant use of systemic antibiotics or .
  • Active ocular infection or allergy.
  • Previous surgery on the eyelids such as blepharoplasty.
  • Abraded skin on or around the eyelids.
  • Patients unable to close eyes or uncontrolled blinking.
  • Previous allergic reaction to TTO-containing products or cosmetic fragrance.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cliradex® eyelid hygiene

    Cliradex® is a novel over-the-counter eyelid wipe which contains the most active ingredient of TTO. Previous studies have shown the clinical and antimicrobial efficacy of eyelid hygiene with tea tree oil (TTO) in resolving chronic blepharitis.

    Other: Tea Tree Oil (TTO)

  • Other
    I-Lid 'n Lash® Hygiene

    Lid 'n Lash® Hygiene, is an over-the-counter eyelid wipe, without any medicinal ingredients,

    Other: I-Lid'n Lash® Hygiene

Interventions

  • OtherTea Tree Oil (TTO)

    Participants will use the Cliradex® eyelid hygiene lid wipe / towelette for BID for 2 weeks

  • OtherI-Lid'n Lash® Hygiene

    Patients will use the I-Lid'n Lash® Hygiene lid wipe / towelette for BID for 2 weeks

06

What researchers measure

Primary outcomes

  1. Evidence of microbiologic improvement

    difference in change in the number of CFU's after 2 weeks treatment, between the groups. (Note: colony counts over 200 will not be counted but reported as \>200)

    Time frame: 2 weeks

Secondary outcomes

  1. Improvement in signs & symptoms of blepharitis based on visual grading scale

    The Secondary Outcome Measure will be the difference in change in objective clinical signs and symptoms using a visual grading scale

    Time frame: 2 weeks

  2. Improvement in signs & symptoms of blepharitis based on participant questionnaire

    The Secondary Outcome Measure will be the difference in change in objective clinical signs and symptoms using a questionnaire after 2 weeks treatment between the groups.

    Time frame: 2 weeks

Other outcomes

  1. Evidence of continued microbiologic improvement after discontinuing blepharitis treatment

    difference in change in the number of CFU's at 2 \& 4 weeks post discontinuation of treatment, between the groups. (Note: colony counts over 200 will not be counted but reported as \>200)

    Time frame: 2 & 4 weeks post discontinuation of treatment

  2. Evidence of continued improvement in signs & symptoms of blepharitis, based on grading scale, after discontinuing blepharitis treatment

    The Outcome Measure will be the difference in change in objective clinical signs and symptoms using a visual grading scale

    Time frame: 2 & 4 weeks post discontinuation of treatment

  3. Evidence of continued improvement in signs & symptoms of blepharitis, based on participant questionnaire, after discontinuing blepharitis treatment

    The Outcome Measure will be the difference in change in objective clinical signs and symptoms using a questionnaire

    Time frame: 2 & 4 weeks post discontinuation of treatment

07

Study locations

1 of 1 sites recruiting
  • Ottawa Health Research Institute
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
    • Annelise M Saunders, CCRP · Contactansaunders@toh.ca · 613-737-8657
    • Setareh Ziai, MD · Principal investigator
    • Yufeng Chen, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2017 (actual). Primary completion is estimated for Jan 2019, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2017
First posted
Feb 5, 2018
StartActual
Feb 19, 2017
Primary completionEst.
Jan 2019
CompletionEst.
Jan 2019
Last update
Feb 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03422146
Responsible party
Sponsor
First posted
Feb 5, 2018
Start date
Feb 19, 2017
Primary completion
Jan 2019 (estimated)
Completion
Jan 2019 (estimated)
Last update
Feb 5, 2018

Study contacts

Annelise M Saunders, CCRP
Contact
ansaunders@toh.ca
613-737-8657
Melanie Lalonde, PhD
Contact
mlalonde@ohri.ca
613-737-8519
Setareh Ziai, MD
principal investigator · Ottawa Hospital Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion